HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $50
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $21 to $50.
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $21 to $50.